1536200-31-3 Usage
Description
GNE-9605 is an orally bioavailable and potent inhibitor of leucine-rich repeat kinase 2 (LRRK2) with high selectivity over other kinases. It has demonstrated effectiveness in inhibiting LRRK2 Ser1292 autophosphorylation in BAC transgenic mice expressing human LRRK2 protein with the G2019S mutation, which is associated with autosomal Parkinson's disease.
Uses
Used in Pharmaceutical Industry:
GNE-9605 is used as a therapeutic agent for the treatment of Parkinson's disease. Its application is based on its ability to selectively inhibit the LRRK2 enzyme, which is implicated in the pathogenesis of the disease, particularly in cases with the G2019S mutation.
Used in Research and Development:
GNE-9605 is used as a research tool for studying the role of LRRK2 in Parkinson's disease and other related neurodegenerative disorders. Its high selectivity for LRRK2 makes it a valuable compound for investigating the enzyme's function and potential therapeutic targets.
Used in Drug Discovery and Development:
GNE-9605 serves as a lead compound in the development of new drugs targeting LRRK2 for the treatment of Parkinson's disease and other conditions related to LRRK2 dysregulation. Its potent inhibition and selectivity make it a promising starting point for further optimization and development of more effective and safer therapeutics.
references
[1]. estrada aa, chan bk, baker-glenn c, et al. discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (lrrk2) small molecule inhibitors. j med chem, 2014, 57(3): 921-936.
Check Digit Verification of cas no
The CAS Registry Mumber 1536200-31-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,5,3,6,2,0 and 0 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1536200-31:
(9*1)+(8*5)+(7*3)+(6*6)+(5*2)+(4*0)+(3*0)+(2*3)+(1*1)=123
123 % 10 = 3
So 1536200-31-3 is a valid CAS Registry Number.
1536200-31-3Relevant articles and documents
Discovery of highly potent, selective, and brain-penetrant aminopyrazole Leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors
Estrada, Anthony A.,Chan, Bryan K.,Baker-Glenn, Charles,Beresford, Alan,Burdick, Daniel J.,Chambers, Mark,Chen, Huifen,Dominguez, Sara L.,Dotson, Jennafer,Drummond, Jason,Flagella, Michael,Fuji, Reina,Gill, Andrew,Halladay, Jason,Harris, Seth F.,Heffron, Timothy P.,Kleinheinz, Tracy,Lee, Donna W.,Pichon, Claire E. Le,Liu, Xingrong,Lyssikatos, Joseph P.,Medhurst, Andrew D.,Moffat, John G.,Nash, Kevin,Scearce-Levie, Kimberly,Sheng, Zejuan,Shore, Daniel G.,Wong, Susan,Zhang, Shuo,Zhang, Xiaolin,Zhu, Haitao,Sweeney, Zachary K.
, p. 921 - 936 (2014/03/21)
Leucine-rich repeat kinase 2 (LRRK2) has drawn significant interest in the neuroscience research community because it is one of the most compelling targets for a potential disease-modifying Parkinson's disease therapy. Herein, we disclose structurally div
